Alumis Inc. (ALMS) Cash Flow Statement

NASDAQ: ALMSOperating cash, capex, free cash flow and buybacks.

Where ALMS’s cash came from and went, 2025

December 31, 2025 · U.S. dollars
Cash from operations
−$369.5M
Capital expenditures
$653,000
2.7% of revenue
Free cash flow
−$370.2M
−1,539.2% margin
Returned to shareholders
$17,000
Change in cash
−$79.6M
cash at year-end $91.1M
Investments (net): $238.8MInvestments (net)$238.8MAcquisitions & other: $49.7MAcquisitions & other$49.7MDrawn from cash: $79.6MDrawn from cash$79.6MOther financing: $2.1MOther financing$2.1MCash used in operations: $369.5MCash used in operations$369.5M · 100%Capital expenditures: $653,000Capital expenditures$653,000 · 0%$370.2M
Cash from operations
−$369.5M
Investments (net)
+$238.8M
Acquisitions & other
+$49.7M
Other financing
+$2.1M
Change in cash
−$79.6M

Drawn to scale: where the cash came from and how it was used. Hover for values.

ALMS operating cash flow, capex and free cash flow

Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)

ALMS cash flow trends, 2022–2025

Alumis Inc. cash flow trends
MetricTrendThenLatestChange
Operating cash flow−$107.7M2022−$369.5M2025—
Capital expenditures$2.4M2022$653,0002025−35.3%/yr
Free cash flow−$110.1M2022−$370.2M2025—
Stock-based compensation$6.0M2022$43.5M2025+94.0%/yr
Share buybacks (net)$64,0002023$17,0002025−48.5%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

ALMS cash flow by activity

OperatingInvestingFinancingChange in cash

ALMS net income vs operating cash flow

Net incomeOperating cash flow

Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).

ALMS cash flow statement

Alumis Inc. annual cash flow statement
2025202420232022
Operating activities
Net income−$243.3M−$294.2M−$155.0M−$111.9M
Depreciation & amortization$3.5M$3.2M$1.3M$250,000
Stock-based compensation$43.5M$19.5M$8.6M$6.0M
Change in working capital$26.3M$14.8M$12.1M−$1.9M
Other non-cash items−$199.5M$1.8M$3.1M−$86,000
Cash from operating activities−$369.5M−$255.1M−$130.0M−$107.7M
Investing activities
Capital expenditures−$653,000−$1.7M−$4.5M−$2.4M
Investments (net)$238.8M−$113.8M$60.5M−$68.8M
Acquisitions & other investing$49.7M$1.7M$4.5M$2.4M
Cash from investing activities$287.9M−$113.8M$60.5M−$68.8M
Financing activities
Share repurchases & issuance (net)−$17,000—−$64,000—
Shares issued$0$451.8M$89.8M$99.9M
Other financing$2.1M$40.6M−$32,000$1.7M
Cash from financing activities$2.1M$492.4M$89.7M$101.6M
Summary
Net change in cash−$79.6M$123.5M$20.2M−$74.8M
Cash at end of period$91.1M$170.6M$47.1M$27.0M
Free cash flow−$370.2M−$256.8M−$134.5M−$110.1M
Free cash flow margin−1,539.2%———
Capex / revenue2.7%———

Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.

ALMS cash generation

In fiscal 2025 (ended December 31, 2025), Alumis generated -$369.5 million of cash from operations and spent $0.7 million on capital expenditures, leaving free cash flow of -$370.2 million, −1,539.2% of revenue. It returned $0.0 million to shareholders through dividends ($0) and net share buybacks ($0.0 million). Cash and equivalents fell by $79.6 million over the year.

Related: ALMS income statement, ALMS balance sheet. See the ALMS stock overview for the latest quote and news.

ALMS cash flow FAQ

What is Alumis's free cash flow?

Alumis's free cash flow was -$370.2 million in fiscal 2025: -$369.5 million of operating cash flow minus $0.7 million of capital expenditures It was -$256.8 million a year earlier..

How much cash does Alumis generate from operations?

Alumis generated -$369.5 million of cash from operating activities in fiscal 2025.

How much does Alumis spend on capital expenditures?

Alumis spent $0.7 million on capital expenditures in fiscal 2025, 2.7% of revenue, compared with $1.7 million the year before.

How much stock does Alumis buy back?

Alumis spent $0.0 million on net share repurchases in fiscal 2025.

Biotechnology: cash flow